Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Hypermorphic mutation of phospholipase C, ?2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.

Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ. Hypermorphic mutation of phospholipase C, ?2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015 Jul 02; 126(1):61-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.